منابع مشابه
Watch What I Watch
This paper presents a high-level overview of Yahoo Research Berkeley’s approach to multimedia research and the ideas motivating it. This approach is characterized primarily by a shift away from building subsystems that attempt to discover or understand the “meaning” of media content toward systems and algorithms that can usefully utilize information about how media content is being used in spec...
متن کاملAntibodies to watch in 2017
Over 50 investigational monoclonal antibody (mAb) therapeutics are currently undergoing evaluation in late-stage clinical studies, which is expected to drive a trend toward first marketing approvals of at least 6-9 mAbs per year in the near-term. In the United States (US), a total of 6 and 9 mAbs were granted first approvals during 2014 and 2015, respectively; all these products are also approv...
متن کاملA young scientist to watch.
There are many rewards associated with serving as the Editor of the Journal of Environmental Quality ( JEQ), but I have experienced very few that compare with the pleasure associated with writing this Letter from the Editor introducing you to a new young scientist that you should keep an eye on. On 7 September 2010, I received an e-mail from ASA Editorin-Chief Dr. Warren Dick containing a PDF f...
متن کاملAntibodies to watch in 2013
The transitions of antibody therapeutics to late-stage clinical development, regulatory review and the market are proceeding at a rapid pace in 2013. Since late 2012, two monoclonal antibody (mAb) therapeutics (itolizumab, trastuzumab emtansine) received their first approvals, first marketing applications for three mAbs (vedolizumab, ramucirumab, obinutuzumab) were submitted to regulatory agenc...
متن کاملAntibodies to watch in 2018
The pace of antibody therapeutics development accelerated in 2017, and this faster pace is projected to continue through 2018. Notably, the annual number of antibody therapeutics granted a first approval in either the European Union (EU) or United States (US) reached double-digits (total of 10) for the first time in 2017. The 10 antibodies granted approvals are: brodalumab, dupilumab, sarilumab...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nurse Leader
سال: 2018
ISSN: 1541-4612
DOI: 10.1016/j.mnl.2018.01.002